BioNTech says has supplied more than 1 bln COVID-19 vaccine doses so far

Reuters2021-08-09

FRANKFURT, Aug 9 (Reuters) - BioNTech and partner Pfizer have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca , the German biotech group said on Monday.

AstraZeneca said on July 29 that it and its manufacturing partner, India-based Serum Institute, had supplied a billion doses to 170 countries at the time.

Based on delivery contracts so far, BioNTech said in a statement it expects 15.9 billion euros ($18.7 billion) in revenue accruing to it from the vaccine this year, up from a forecast in May of 12.4 billion euros.

That includes sales, milestone payments from partners and a share of gross profit in its partners' territories, the company added. ($1 = 0.8509 euros)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

  • TK360
    2021-08-10
    TK360
    Nice 
  • Chanyt
    2021-08-09
    Chanyt
    [Smile] 
  • Firefire
    2021-08-09
    Firefire
    Great!
  • Sumei
    2021-08-09
    Sumei
    BNTX has a lot more growth potential in my opinion. It is a biotechnology company that’s actually focused in developing treatments for cancer. And finding treatments for cancer is a huge industry. 
  • 股市搜搜搜
    2021-08-09
    股市搜搜搜
    Good
Leave a comment
24